Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT
- Kharfan-Dabaja, M.A.
- Labopin, M.
- Bazarbachi, A.
- Hamladji, R.M.
- Blaise, D.
- Socié, G.
- Lioure, B.
- Bermudez, A.
- Lopez-Corral, L.
- Or, R.
- Arcese, W.
- Fegueux, N.
- Nagler, A.
- Mohty, M.
ISSN: 1476-5365
Argitalpen urtea: 2014
Alea: 49
Zenbakia: 9
Orrialdeak: 1170-1175
Mota: Artikulua